Original Articles

You have full text access to this OnlineOpen article

Unexplained and prolonged perioperative hypotension after orthotopic liver transplantation: Undiagnosed systemic mastocytosis

  1. Darrin L. Willingham1,†,*,
  2. Prith Peiris2,
  3. Juan M. Canabal3,4,
  4. Murli Krishna5,
  5. Winston R. Hewitt1,
  6. Timothy S. J. Shine2,
  7. Lisa C. Arasi4,
  8. Jaime Aranda-Michel4,
  9. Christopher B. Hughes1,
  10. David J. Kramer3,4

Article first published online: 26 JUN 2009

DOI: 10.1002/lt.21762

Issue

Liver Transplantation

Liver Transplantation

Volume 15, Issue 7, pages 701–708, July 2009

Additional Information

How to Cite

Willingham, D. L., Peiris, P., Canabal, J. M., Krishna, M., Hewitt, W. R., Shine, T. S. J., Arasi, L. C., Aranda-Michel, J., Hughes, C. B. and Kramer, D. J. (2009), Unexplained and prolonged perioperative hypotension after orthotopic liver transplantation: Undiagnosed systemic mastocytosis. Liver Transpl, 15: 701–708. doi: 10.1002/lt.21762

Author Information

  1. 1

    Division of Transplant Surgery, Mayo Clinic, Jacksonville, FL

  2. 2

    Department of Anesthesiology, Mayo Clinic, Jacksonville, FL

  3. 3

    Department of Critical Care, Mayo Clinic, Jacksonville, FL

  4. 4

    Division of Transplant Medicine, Mayo Clinic, Jacksonville, FL

  5. 5

    Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, FL

  1. †

    Telephone: 507-284-8917; FAX: 507-284-2107

*Department of Transplantation, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224

Publication History

  1. Issue published online: 26 JUN 2009
  2. Article first published online: 26 JUN 2009
  3. Manuscript Accepted: 11 JAN 2009
  4. Manuscript Received: 17 JUL 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (571K)

REFERENCES

  • 1
    Horny HP, Sotlar K, Valent P. Mastocytosis: state of the art. Pathobiology 2007; 74: 121–132.
  • 2
    Kyriakou D, Kouroumalis E, Konsolas J, Oekonomaki H, Tzardi M, Kanavaros P, et al. Systemic mastocytosis: a rare cause of noncirrhotic portal hypertension simulating autoimmune cholangitis: report of four cases. Am J Gastroenterol 1998; 93: 106–108.
  • 3
    Capron JP, Lebrec D, Degott C, Chivrac D, Coevoet B, Delobel J. Portal hypertension in systemic mastocytosis. Gastroenterology 1978; 74: 595–597.
  • 4
    Narayanan MN, Liu Yin JA, Azzawi S, Warnes TW, Turck WP. Portal hypertension and ascites in systemic mastocytosis. Postgrad Med J 1989; 65: 394–396.
  • 5
    Escribano L, Akin C, Castells M, Orfao A, Metcalfe DD. Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol 2002; 81: 677–690.
  • 6
    Horny HP, Ruck M, Wehrmann M, Kaiserling E. Blood findings in generalized mastocytosis: evidence of frequent simultaneous occurrence of myeloproliferative disorders. Br J Haematol 1990; 76: 186–193.
    Direct Link:
  • 7
    McElroy EA Jr, Phyliky RL, Li CY. Systemic mast cell disease associated with the hypereosinophilic syndrome. Mayo Clin Proc 1998; 73: 47–50.
  • 8
    Miranda RN, Esparza AR, Sambandam S, Medeiros LJ. Systemic mast cell disease presenting with peripheral blood eosinophilia. Hum Pathol 1994; 25: 727–730.
  • 9
    Pardanani A, Reeder T, Li CY, Tefferi A. Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia. Leuk Res 2003; 27: 883–885.
  • 10
    Tefferi A, Pardanani A, Li CY. Hypereosinophilic syndrome with elevated serum tryptase versus systemic mast cell disease associated with eosinophilia: 2 distinct entities? Blood 2003; 102: 3073–3074.
  • 11
    Vejlgaard TB. Systemic mastocytosis with eosinophilia [in Danish]. Ugeskr Laeger 1996; 158: 782–783.
  • 12
    Yam LT, Yam CF, Li CY. Eosinophilia in systemic mastocytosis. Am J Clin Pathol 1980; 73: 48–54.
  • 13
    Patnaik MM, Rindos M, Kouides PA, Tefferi A, Pardanani A. Systemic mastocytosis: a concise clinical and laboratory review. Arch Pathol Lab Med 2007; 131: 784–791.
  • 14
    Valent P, Akin C, Escribano L, Fodinger M, Hartmann K, Brockow K, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007; 37: 435–453.
    Direct Link:
  • 15
    Valent P, Akin C, Sperr WR, Mayerhofer M, Födinger M, Fritsche-Polanz R, et al. Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma 2005; 46: 35–48.
  • 16
    JaffeeES, HarrisNL, SteinH, VardimanJW, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press: 2001: 293–302.
  • 17
    Patnaik MM, Tefferi A, Pardanani A. Kit: molecule of interest for the diagnosis and treatment of mastocytosis and other neoplastic disorders. Curr Cancer Drug Targets 2007; 7: 492–503.
  • 18
    Butterfield JH. Response of severe systemic mastocytosis to interferon alpha. Br J Dermatol 1998; 138: 489–495.
    Direct Link:
  • 19
    Hauswirth AW, Simonitsch-Klupp I, Uffmann M, Koller E, Sperr WR, Lechner K, et al. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leuk Res 2004; 28: 249–257.
  • 20
    Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003; 102: 3093–3096.
  • 21
    Gotlib J, Berube C, Growney JD, Chen CC, George TI, Williams C, et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 2005; 106: 2865–2870.
View Full Article (HTML) Get PDF (571K)